Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study

Jermann, M.; Jost, L. M.; Taverna, Ch.; Jacky, E.; Honegger, H. P.; Betticher, D. C.; Egli, F.; Kroner, Th.; Stahel, R. A. (2004). Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Annals of oncology, 15(3), pp. 511-516. Oxford University Press 10.1093/annonc/mdh093

[img]
Preview
Text
mdh093.pdf - Published Version
Available under License Publisher holds Copyright.

Download (228kB) | Preview

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Betticher, Daniel

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0923-7534

Publisher:

Oxford University Press

Language:

English

Submitter:

Markus Müller

Date Deposited:

01 Oct 2018 15:42

Last Modified:

01 Oct 2018 15:42

Publisher DOI:

10.1093/annonc/mdh093

BORIS DOI:

10.7892/boris.115567

URI:

https://boris.unibe.ch/id/eprint/115567

Actions (login required)

Edit item Edit item
Provide Feedback